Evidence map›Paper›PMID 38997253›Full record

ArticleNature communications2024

Asymmetric total synthesis of polycyclic xanthenes and discovery of a WalK activator active against MRSA.

Min-Jing Cheng, Yan-Yi Wu, Hao Zeng, Tian-Hong Zhang, Yan-Xia Hu, Shi-Yi Liu, Rui-Qin Cui, Chun-Xia Hu, Quan-Ming Zou, Chuang-Chuang Li and 3 more

Abstract read
In one paragraph

Article in Nature communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Min-Jing Cheng *State Key Laboratory of Bioactive Molecules and Druggability Assessment, Jinan University, Guangzhou, 510632, P. R. China.ORCID 0009-0008-0072-7433
Yan-Yi Wu *State Key Laboratory of Bioactive Molecules and Druggability Assessment, Jinan University, Guangzhou, 510632, P. R. China.
Hao Zeng *National Engineering Research Center of Immunological Products, Department of Microbiology and Biochemical Pharmacy, College of Pharmacy, Army Medical University, Chongqing, 400038, P. R. China.
Tian-Hong ZhangState Key Laboratory of Bioactive Molecules and Druggability Assessment, Jinan University, Guangzhou, 510632, P. R. China.
Yan-Xia HuState Key Laboratory of Bioactive Molecules and Druggability Assessment, Jinan University, Guangzhou, 510632, P. R. China.
Shi-Yi LiuDepartment of Medical Laboratory, Shenzhen People's Hospital (The Second Clinical Medical College, Jinan University; The First Affiliated Hospital, Southern University of Science and Technology), Shenzhen, 518020, Guangdong, P. R. China.
Rui-Qin CuiDepartment of Medical Laboratory, Shenzhen People's Hospital (The Second Clinical Medical College, Jinan University; The First Affiliated Hospital, Southern University of Science and Technology), Shenzhen, 518020, Guangdong, P. R. China.
Chun-Xia HuDepartment of Medical Laboratory, Shenzhen People's Hospital (The Second Clinical Medical College, Jinan University; The First Affiliated Hospital, Southern University of Science and Technology), Shenzhen, 518020, Guangdong, P. R. China.
Quan-Ming ZouNational Engineering Research Center of Immunological Products, Department of Microbiology and Biochemical Pharmacy, College of Pharmacy, Army Medical University, Chongqing, 400038, P. R. China. qmzou2007@163.com.ORCID 0000-0002-6971-0786
Chuang-Chuang LiDepartment of Chemistry, Shenzhen Grubbs Institute, Southern University of Science and Technology, Shenzhen, 518055, P. R. China. ccli@sustech.edu.cn.ORCID 0000-0003-4344-0498
Wen-Cai YeState Key Laboratory of Bioactive Molecules and Druggability Assessment, Jinan University, Guangzhou, 510632, P. R. China. chywc@aliyun.com.ORCID 0000-0002-2810-1001
Wei HuangDepartment of Medical Laboratory, Shenzhen People's Hospital (The Second Clinical Medical College, Jinan University; The First Affiliated Hospital, Southern University of Science and Technology), Shenzhen, 518020, Guangdong, P. R. China. whuang_sz@163.com.ORCID 0000-0002-8569-5184
Lei WangState Key Laboratory of Bioactive Molecules and Druggability Assessment, Jinan University, Guangzhou, 510632, P. R. China. cpuwanglei@126.com.ORCID 0000-0001-9242-1109

Funding

National Natural Science Foundation of China (National Science Foundation of China) 81822042National Natural Science Foundation of China (National Science Foundation of China) 82104019National Natural Science Foundation of China (National Science Foundation of China) 82173859National Natural Science Foundation of China (National Science Foundation of China) 82293681(82293680)
6 · The paper itself

Abstract

The development of new antibiotics continues to pose challenges, particularly considering the growing threat of multidrug-resistant Staphylococcus aureus. Structurally diverse natural products provide a promising source of antibiotics. Herein, we outline a concise approach for the collective asymmetric total synthesis of polycyclic xanthene myrtucommulone D and five related congeners. The strategy involves rapid assembly of the challenging benzopyrano[2,3-a]xanthene core, highly diastereoselective establishment of three contiguous stereocenters through a retro-hemiketalization/double Michael cascade reaction, and a Mitsunobu-mediated chiral resolution approach with high optical purity and broad substrate scope. Quantum mechanical calculations provide insight into stereoselective construction mechanism of the three contiguous stereocenters. Additionally, this work leads to the discovery of an antibacterial agent against both drug-sensitive and drug-resistant S. aureus. This compound operates through a unique mechanism that promotes bacterial autolysis by activating the two-component sensory histidine kinase WalK. Our research holds potential for future antibacterial drug development.

Indexed as

Anti-Bacterial AgentsMethicillin-Resistant Staphylococcus aureusXanthenesDrug DiscoveryMicrobial Sensitivity TestsMolecular StructurePolycyclic CompoundsStereoisomerismAnti-Bacterial AgentsPolycyclic CompoundsXanthenes

Identifiers

PMID38997253
PMCPMC11245619

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.